Coloplast在2024/25年有机地增长了7%的收入,利润丰厚,股息增加,预计2025/26年将继续增长。 Coloplast grew revenue 7% organically in 2024/25, with strong profits and a dividend increase, projecting continued growth for 2025/26.

丹麦医疗设备公司Coloplast报告了2024/25财政结果,有机收入增长7%,EBIT比值28%,比上一年27%有所增加。 Danish medical device company Coloplast reported fiscal 2024/25 results with 7% organic revenue growth and a 28% EBIT margin, up from 27% the prior year. 收入增长了3%,达到278.7亿丹麦克朗,其驱动力是所有商业单位的强劲业绩,尽管干预性乌鲁症因产品被召回而面临挑战。 Revenue rose 3% to DKK 27.87 billion, driven by strong performance across all business units, though Interventional Urology faced challenges from a product recall. 经调整的EBIT达到7.67亿丹麦克朗,增加了5%,调整后的每股收入增加了2%,达到22.84丹麦克朗。 Adjusted EBIT reached DKK 7.67 billion, up 5%, and adjusted earnings per share rose 2% to DKK 22.84. 该公司维持了19%经调整的自由现金流通与销售比率,并建议年度总红利为23.00丹麦克朗。 The company maintained a 19% adjusted free cash flow-to-sales ratio and recommended a total annual dividend of DKK 23.00. 就2025/26年而言,Coloplast公司预测约7%的有机收入和EBIT以固定货币计算的增长,预计该组织将达到16%。 For 2025/26, Coloplast projects around 7% organic revenue and EBIT growth in constant currencies, with ROIC expected to reach 16%.